Geron GERN
NASDAQ GERN
$1.38 -0.02 (-1.78%)
As of: Sep 10, 2026 · 3:59 PM EDT

Geron (GERN) Non-Current Debt (2011 - 2026)

Geron's (GERN) quarterly Non-Current Debt came in at $120.1 million in Q2 2026, up 0.96% year-over-year from $119.0 million in Q2 2025, and little changed quarter-over-quarter from $119.8 million in Q1 2026.

Analysis

Geron (GERN) Non-Current Debt (2011 - 2026) Analysis & Trends

Geron has disclosed Non-Current Debt across 8 years of filings, most recently posting $120.1 million for Q2 2026.

  • In Q2 2026, Non-Current Debt rose 0.96% year-over-year to $120.1 million; the TTM figure through Jun 2026 stood at $120.1 million (up 0.96% YoY), while the FY2025 annual figure was $119.5 million, up 0.9% from the prior year.
  • Non-Current Debt came in at $120.1 million for Q2 2026 at Geron, roughly flat from $119.8 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $120.1 million in Q2 2026 to a low of $11.2 million in Q1 2024.
  • Average Non-Current Debt over 5 years is $67.5 million, with a median of $47.7 million recorded in 2022.
  • Year-over-year, Non-Current Debt tumbled 78.17% in 2024 and jumped 958.28% in 2025.
  • Over 5 years, Non-Current Debt stood at $30.2 million in 2022, then advanced by 16.02% to $35.1 million in 2023, then soared by 238.01% to $118.5 million in 2024, then climbed by 0.9% to $119.5 million in 2025, then increased by 0.49% to $120.1 million in 2026.
  • Per Business Quant data, the three most recent Non-Current Debt figures were $120.1 million in Q2 2026, $119.8 million in Q1 2026, and $119.5 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 57.30 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 26.25 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 1.99 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 591.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 7.29 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Geron 914.60 Mn 613.75 Mn - 120.13 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 120.13 Mn
Mar 31, 2026 119.83 Mn
Dec 31, 2025 119.55 Mn
Sep 30, 2025 119.26 Mn
Jun 30, 2025 118.99 Mn
Mar 31, 2025 118.73 Mn
Dec 31, 2024 118.48 Mn
Sep 30, 2024 12.28 Mn
Jun 30, 2024 36.52 Mn
Mar 31, 2024 11.22 Mn
Dec 31, 2023 35.05 Mn
Sep 30, 2023 29.84 Mn
Jun 30, 2023 40.80 Mn
Mar 31, 2023 51.40 Mn
Dec 31, 2022 30.21 Mn
Sep 30, 2022 37.80 Mn
Jun 30, 2022 45.26 Mn
Mar 31, 2022 50.18 Mn
Dec 31, 2021 49.83 Mn
Sep 30, 2021 34.67 Mn